^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | zanidatamab zovodotin (ZW49) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Excerpt:
In a 3+3 design, patients (pts) with HER2+ cancers were dosed with ZW49 IV QW…Overall, the most common histologies were gastric (28%) and breast (22%) cancers...the confirmed objective response rate across multiple cancer types was 28% and disease control rate was 72%....ZW49 has a manageable safety profile with encouraging single-agent antitumor activity in heavily pretreated pts with HER2+ cancers.
DOI:
https://doi.org/10.1016/j.annonc.2022.07.589
Trial ID:
